Cargando…
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is associated with a high mortality rate and presents a major challenge for human health. Activation of multiple oncogenes has been reported to be strongly associated with the progression of HCC. Moreover, the immunosuppressive tumor microenvironment (TME) and the host...
Autores principales: | Shao, Liwei, Yu, Xin, Han, Qiuju, Zhang, Xinke, Lu, Nan, Zhang, Cai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746623/ https://www.ncbi.nlm.nih.gov/pubmed/36524206 http://dx.doi.org/10.1080/2162402X.2021.2010894 |
Ejemplares similares
-
Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma
por: Xia, Lijie, et al.
Publicado: (2020) -
GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016) -
Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
por: Li, You-Cai, et al.
Publicado: (2018) -
Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017) -
Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)